Tukavo (Tucatinib 150mg) is a targeted therapy used to treat HER2-positive advanced and metastatic breast cancer, usually in combination with other medicines.
| Composition | Tucatinib |
| Manufacturer | Zydus |
| Packing | 60 Tablets |
| Prescribed For | HER2-positive metastatic breast cancer |
| Expiry | December 2027 |
Tucanat contains Tucatinib, a targeted therapy used to treat HER2-positive breast cancer, often in combination with other medicines. It helps slow cancer growth, prevent spread, and improve survival in advanced or metastatic cases.
| Composition | Tucatinib |
| Manufacturer | Natco |
| Packing | 60 Tablets |
| Prescribed For | HER2-positive metastatic breast cancer |
| Expiry | December 2027 |
Lenalid contains Lenalidomide 25mg, a prescription medicine used to treat certain types of blood cancers, including multiple myeloma, myelodysplastic syndromes (MDS), and mantle cell lymphoma (MCL).
| Composition | Lenalidomide |
| Manufacturer | Natco Pharma Ltd |
| Packing | 30 Capsules in 1 Bottle |
| Prescribed For | Multiple myeloma |
| Expiry | December 2027 |
Lenakast (Lenalidomide 25 mg) is an oral immunomodulatory medicine used in the treatment of multiple myeloma and certain blood disorders. It helps slow cancer cell growth, supports immune response, and is commonly used as part of combination therapy under medical supervision.
| Composition | Lenalidomide |
| Manufacturer | Aprazer Healthcare Pvt Ltd |
| Packing | 30 Capsules in 1 Bottle |
| Prescribed For | Multiple myeloma |
| Expiry | December 2027 |
Ibrunat contains Ibrutinib 140mg, a targeted cancer therapy used to treat certain blood cancers such as Chronic Lymphocytic Leukemia (CLL), Mantle Cell Lymphoma (MCL), and Waldenström’s Macroglobulinemia (WM).
| Composition | Ibrutinib |
| Manufacturer | Natco Pharma Ltd |
| Packing | 30 Capsules |
| Prescribed For | Blood Cancers |
| Expiry | December 2027 |
Imat contains Imatinib 400mg, a targeted chemotherapy medicine used to treat certain types of cancers, including chronic myeloid leukemia (CML) and gastrointestinal stromal tumors (GISTs).
| Composition | Imatinib |
| Manufacturer | Zydus Healthcare Limited |
| Packing | 120 Tablets |
| Prescribed For | Chronic Myeloid Leukemia and Gastrointestinal Stromal Tumors |
| Expiry | December 2027 |
Imatikast contains Imatinib 400mg, a targeted cancer therapy used to treat certain types of cancers such as Chronic Myeloid Leukemia (CML), Acute Lymphoblastic Leukemia (ALL), and Gastrointestinal Stromal Tumors (GISTs).
| Composition | Imatinib |
| Manufacturer | Aprazer Healthcare Pvt Ltd |
| Packing | 10 Tablets in 1 Strip |
| Prescribed For | Chronic Myeloid Leukemia, Acute Lymphoblastic Leukemia, Gastrointestinal Stromal Tumors |
| Expiry | December 2027 |
Invista contains Dasatinib 100mg, a targeted cancer medication used in the treatment of certain types of blood cancers, including Chronic Myeloid Leukemia (CML) and Acute Lymphoblastic Leukemia (ALL) that are Philadelphia chromosome-positive.
| Composition | Dasatinib |
| Manufacturer | Dr Reddy’s Laboratories Ltd |
| Packing | 30 Tablets |
| Prescribed For | Chronic Myeloid Leukemia |
| Expiry | December 2027 |
Lenangio contains Lenalidomide 25mg, a medicine used to treat certain types of blood cancers such as multiple myeloma, myelodysplastic syndromes (MDS), and mantle cell lymphoma (MCL).
| Composition | Lenalidomide |
| Manufacturer | Dr Reddy’s Laboratories Ltd |
| Packing | 10 Capsules |
| Prescribed For | Multiple Myeloma, Myelodysplastic Syndrome and Mantle Cell Lymphoma |
| Expiry | December 2027 |
Leu Kinib contains Dasatinib 70mg, a targeted therapy used for treating certain types of blood cancers such as Chronic Myeloid Leukemia (CML) and Philadelphia chromosome-positive Acute Lymphoblastic Leukemia (Ph+ ALL).
| Composition | Dasatinib |
| Manufacturer | Sayre Therapeutics Pvt Ltd |
| Packing | 60 Tablets |
| Prescribed For | Blood Cancer |
| Expiry | December 2027 |
Nextki contains Dasatinib 100mg, a targeted cancer therapy used to treat certain blood cancers, specifically Chronic Myeloid Leukemia (CML) and Philadelphia chromosome-positive Acute Lymphoblastic Leukemia (Ph+ ALL).
| Composition | Dasatinib |
| Manufacturer | Emcure Pharmaceuticals Ltd |
| Packing | 30 Tablets in 1 Bottle |
| Prescribed For | Blood Cancer |
| Expiry | December 2027 |
Nitib contains Ibrutinib 140mg, a targeted therapy used to treat certain types of blood cancers, including chronic lymphocytic leukemia (CLL), mantle cell lymphoma (MCL), and Waldenström’s macroglobulinemia.
| Composition | Ibrutinib |
| Manufacturer | Hetero Healthcare Limited |
| Packing | 30 Capsules |
| Prescribed For | Blood Cancer |
| Expiry | December 2027 |
Pomalid contains Pomalidomide 2mg, an immunomodulatory drug used in the treatment of multiple myeloma (a type of blood cancer), especially in patients who have not responded to other therapies such as lenalidomide and bortezomib.
| Composition | Pomalidomide |
| Manufacturer | Natco Pharma Ltd |
| Packing | 21 Capsules in 1 Bottle |
| Prescribed For | Multiple Myeloma |
| Expiry | December 2027 |
Relidomide 25 capsules contains Lenalidomide 25mg, an immunomodulatory medication primarily used in the treatment of certain blood cancers such as multiple myeloma, myelodysplastic syndromes (MDS), and mantle cell lymphoma.
| Composition | Lenalidomide 25mg |
| Manufacturer | Reliance Life Sciences |
| Packing | 21 Capsules |
| Prescribed For | Multiple Myeloma |
| Expiry | December 2027 |
Spnib 50mg/100mg contains dasatinib, a tyrosine kinase inhibitor used to treat certain types of blood cancers, specifically chronic myeloid leukemia (CML) and acute lymphoblastic leukemia (ALL) that are Philadelphia chromosome-positive (Ph+).
| Composition | Dasatinib |
| Manufacturer | Zydus Cadila |
| Packing | 60 Tablets |
| Prescribed For | Blood Cancer |
| Expiry | December 2027 |
Sprycel 50mg contains Dasatinib, a targeted cancer therapy used to treat chronic myeloid leukemia (CML) and Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL).
| Composition | Dasatinib |
| Manufacturer | BMS India Pvt Ltd |
| Packing | 60 Tablets in 1 Bottle |
| Prescribed For | Blood Cancer |
| Expiry | December 2027 |
Daslemia 70 mg is an oral prescription medication that contains dasatinib, a targeted therapy classified as a tyrosine kinase inhibitor (TKI), and it is primarily used in the treatment of Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML) and Ph+ acute lymphoblastic leukemia (Ph+ ALL).
| Composition | Dasatinib |
| Manufacturer | Intas Pharmaceuticals Ltd |
| Packing | 60 Tablets |
| Prescribed For | Blood Cancer |
| Expiry | December 2027 |
Dasatrue 70 mg tablet contains dasatinib and is used to treat certain types of blood cancer, especially chronic myeloid leukemia (CML) and Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL). It helps stop the growth of abnormal white blood cells.
| Composition | Dasatinib |
| Manufacturer | Cipla Ltd |
| Packing | 60 Tablets |
| Prescribed For | Blood Cancer |
| Expiry | December 2027 |
Dasashil 70mg is a prescription cancer medicine that contains Dasatinib, a tyrosine kinase inhibitor (TKI), and it is primarily used in the treatment of chronic myeloid leukemia (CML) and Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL).
| Composition | Dasatinib |
| Manufacturer | Shilpa Medicare Ltd |
| Packing | 60 Tablets in 1 Bottle |
| Prescribed For | Blood Cancer |
| Expiry | December 2027 |
Dasapan 70mg is a prescription medicine that contains Dasatinib, a potent tyrosine kinase inhibitor (TKI) used in the treatment of specific blood cancers. It is primarily prescribed to patients with Chronic Myeloid Leukemia (CML) and Philadelphia chromosome-positive Acute Lymphoblastic Leukemia (Ph+ ALL).
| Composition | Dasatinib |
| Manufacturer | Mankind Pharma Ltd |
| Packing | 60 Tablets in 1 Bottle |
| Prescribed For | Blood Cancer |
| Expiry | December 2027 |
Dasamyl 100 mg contains dasatinib, and it is a targeted therapy medication used in the treatment of certain types of blood cancer, specifically Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML) and Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL).
| Composition | Dasatinib |
| Manufacturer | Mylan Pharmaceuticals Pvt Ltd |
| Packing | 30 Tablets |
| Prescribed For | Blood Cancer |
| Expiry | December 2027 |
| Composition | Dasatinib |
| Manufacturer | AMPS Biotech Pvt Ltd |
| Packing | 60 Tablets |
| Prescribed For | Blood Cancer |
| Expiry | December 2027 |
| Composition | Dasatinib |
| Manufacturer | Aprazer Healthcare Pvt ltd |
| Packing | 60 Tablets |
| Prescribed For | Blood Cancer |
| Expiry | December 2027 |
